Business Context and Reporting Period
This Form 8-K Current Report is filed by Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) on March 16, 2026. The report details a corporate action approved by stockholders via written consent on December 1, 2025, regarding a reverse stock split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment rather than financial performance.
Material Changes
- Reverse Stock Split: The Company approved a 1-for-10 reverse stock split of its issued and outstanding common stock.
- Charter Amendment: The Company's Amended and Restated Certificate of Incorporation will be amended to reflect the split.
- Effective Date: The split is scheduled to become effective at 12:01 a.m. Eastern Time on March 26, 2026.
- Trading Adjustments: Common stock is expected to begin trading on a split-adjusted basis on the NYSE American LLC under the symbol "APUS" at the open of trading on March 26, 2026.
- New CUSIP: The new CUSIP number for the common stock will be 03771D201.
Guidance, Outlook, and Risks
The Company expects to file the Charter Amendment with the Delaware Secretary of State on or about March 25, 2026, following the expiration of a 20-calendar-day waiting period after the mailing of the Information Statement. The Company will announce the effectiveness of the split in a subsequent Form 8-K once the Effective Date occurs. No specific financial guidance or risk factors regarding operations were disclosed in this specific filing.
Investor Verification Checklist
- Verify the exact timing of the 1-for-10 reverse stock split effectiveness (March 26, 2026).
- Confirm the new CUSIP number (03771D201) for trading and settlement purposes.
- Review the definitive Information Statement dated February 26, 2026, for complete details on the reverse stock split.
- Monitor for the subsequent Form 8-K confirming the official effectiveness of the split.